Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth glaucoma drug in short supply

This article was originally published in Scrip

Executive Summary

Wyethis limiting US sales of its glaucoma treatment Phospholine Iodide, 6.25mg (0.125% echothiophate iodide for ophthalmic solution) owing to a product shortage. In a letter to healthcare providers, Wyeth said it expects to be out of the product in the near future, and the outage may be prolonged owing to a delay in supplies of raw material used to make the ophthalmic. The company has initiated a limited distribution plan restricting sales to current patients only, one bottle per patient. Phospholine Iodide, which received FDA approval in 1960, is indicated for treatment of glaucoma and accommodative esotropia. Glaucoma patients using the drug should be instructed to contact their prescribing physicians to seek alternative therapies.

Topics

Related Companies

UsernamePublicRestriction

Register

SC031069

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel